



Express Mail No.: EL 477 037 572 US

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dingivan

Confirmation No.: 6448

Application No.: 10/091,268

Art Unit: 1646

Filed: March 4, 2002

Examiner: To be assigned

For: METHODS OF ADMINISTERING/
DOSING CD2 ANTAGONISTS FOR THE
PREVENTION AND TREATMENT OF
AUTOIMMUNE DISORDERS OR
INFLAMMATORY DISORDERS

Attorney Docket No.: 10271-054

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures ("Notice to Comply") mailed July 25, 2002, Applicant states that the content of the paper and computer readable copies of the Sequence Listed in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, submitted on March 4, 2002 in connection with the above-identified application, is the same. A return copy of the Notice to Comply is included herewith.

No fee is believe due in connection with this response. However, if a fee is due, please charge the Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date August 2, 2002

Anthony M. Insogna 35,203
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, N.Y. 10036-2711
(212) 790-9090

Enclosure

by Margaret B. Brivante
Reg No 40,922